Published in Mol Cell on November 01, 2001
Targeting MET in cancer: rationale and progress. Nat Rev Cancer (2012) 6.43
Endocytosis and signalling: intertwining molecular networks. Nat Rev Mol Cell Biol (2009) 5.83
MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol (2010) 5.44
Regulation of epidermal growth factor receptor down-regulation by UBPY-mediated deubiquitination at endosomes. Mol Biol Cell (2005) 2.31
A direct role for Met endocytosis in tumorigenesis. Nat Cell Biol (2011) 2.11
An overview of the c-MET signaling pathway. Ther Adv Med Oncol (2011) 1.95
HECT and RING finger families of E3 ubiquitin ligases at a glance. J Cell Sci (2012) 1.95
c-MET as a potential therapeutic target and biomarker in cancer. Ther Adv Med Oncol (2011) 1.81
Met/Hepatocyte growth factor receptor ubiquitination suppresses transformation and is required for Hrs phosphorylation. Mol Cell Biol (2005) 1.65
Endocytosis and signaling: cell logistics shape the eukaryotic cell plan. Physiol Rev (2012) 1.61
Endocytosis of receptor tyrosine kinases. Cold Spring Harb Perspect Biol (2013) 1.57
Endosomal dynamics of Met determine signaling output. Mol Biol Cell (2003) 1.55
LRIG1 is a novel negative regulator of the Met receptor and opposes Met and Her2 synergy. Mol Cell Biol (2006) 1.55
Growth factor receptor binding protein 2-mediated recruitment of the RING domain of Cbl to the epidermal growth factor receptor is essential and sufficient to support receptor endocytosis. Mol Biol Cell (2005) 1.49
Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity. Proc Natl Acad Sci U S A (2006) 1.47
HGF-independent potentiation of EGFR action by c-Met. Oncogene (2011) 1.46
The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma. Am J Pathol (2004) 1.43
Protein tyrosine kinase regulation by ubiquitination: critical roles of Cbl-family ubiquitin ligases. Biochim Biophys Acta (2012) 1.39
The carboxyl terminus of VEGFR-2 is required for PKC-mediated down-regulation. Mol Biol Cell (2005) 1.36
FRS2 alpha attenuates FGF receptor signaling by Grb2-mediated recruitment of the ubiquitin ligase Cbl. Proc Natl Acad Sci U S A (2002) 1.36
Entry of Listeria monocytogenes in mammalian epithelial cells: an updated view. Cold Spring Harb Perspect Med (2012) 1.31
GGA3 functions as a switch to promote Met receptor recycling, essential for sustained ERK and cell migration. Dev Cell (2011) 1.31
CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases. PLoS One (2010) 1.25
Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proc Natl Acad Sci U S A (2013) 1.20
Structural characterization of autoinhibited c-Met kinase produced by coexpression in bacteria with phosphatase. Proc Natl Acad Sci U S A (2006) 1.18
Growth factors induce differential phosphorylation profiles of the Hrs-STAM complex: a common node in signalling networks with signal-specific properties. Biochem J (2005) 1.15
TEAD1 and c-Cbl are novel prostate basal cell markers that correlate with poor clinical outcome in prostate cancer. Br J Cancer (2008) 1.13
The function of yeast epsin and Ede1 ubiquitin-binding domains during receptor internalization. Traffic (2010) 1.12
Ubiquitination and degradation of the thrombopoietin receptor c-Mpl. Blood (2009) 1.12
Threshold-controlled ubiquitination of the EGFR directs receptor fate. EMBO J (2013) 1.11
The role of the c-Met pathway in lung cancer and the potential for targeted therapy. Ther Adv Med Oncol (2011) 1.11
Proapoptotic function of the MET tyrosine kinase receptor through caspase cleavage. Mol Cell Biol (2004) 1.09
The UPS in diabetes and obesity. BMC Biochem (2008) 1.08
Structural basis for a novel intrapeptidyl H-bond and reverse binding of c-Cbl-TKB domain substrates. EMBO J (2008) 1.07
Roles of E3 ubiquitin ligases in cell adhesion and migration. Cell Adh Migr (2010) 1.07
MET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition blocks HGF-induced effects in MET mutant cell lines. Br J Cancer (2011) 1.06
A novel multipurpose monoclonal antibody for evaluating human c-Met expression in preclinical and clinical settings. Appl Immunohistochem Mol Morphol (2009) 1.06
Down-regulation of the met receptor tyrosine kinase by presenilin-dependent regulated intramembrane proteolysis. Mol Biol Cell (2009) 1.06
Mechanisms of HGF/Met signaling to Brk and Sam68 in breast cancer progression. Horm Cancer (2012) 0.99
EGF receptor activates MET through MAPK to enhance non-small cell lung carcinoma invasion and brain metastasis. Cancer Res (2013) 0.99
The role of the ubiquitination-proteasome pathway in breast cancer: ubiquitin mediated degradation of growth factor receptors in the pathogenesis and treatment of cancer. Breast Cancer Res (2002) 0.99
The MET axis as a therapeutic target. Update Cancer Ther (2009) 0.98
Nedd4-1 binds and ubiquitylates activated FGFR1 to control its endocytosis and function. EMBO J (2011) 0.97
Distinct recruitment of Eps15 via Its coiled-coil domain is required for efficient down-regulation of the met receptor tyrosine kinase. J Biol Chem (2008) 0.96
Signaling-mediated control of ubiquitin ligases in endocytosis. BMC Biol (2012) 0.95
Exploitation of the ubiquitin system by invading bacteria. Traffic (2010) 0.95
Ubiquitination-dependent regulation of signaling receptors in cancer. Genes Cancer (2010) 0.94
Polyubiquitination of insulin-like growth factor I receptor (IGF-IR) activation loop promotes antibody-induced receptor internalization and down-regulation. J Biol Chem (2011) 0.93
Dorsal ruffle microdomains potentiate Met receptor tyrosine kinase signaling and down-regulation. J Biol Chem (2010) 0.93
EGFRvIII undergoes activation-dependent downregulation mediated by the Cbl proteins. Oncogene (2006) 0.93
Protein-tyrosine phosphatase 1B modulates early endosome fusion and trafficking of Met and epidermal growth factor receptors. J Biol Chem (2011) 0.92
c-Met as a Target for Personalized Therapy. Transl Oncogenomics (2015) 0.92
Activating MET kinase rearrangements in melanoma and Spitz tumours. Nat Commun (2015) 0.92
MUC20 suppresses the hepatocyte growth factor-induced Grb2-Ras pathway by binding to a multifunctional docking site of met. Mol Cell Biol (2004) 0.92
EGFRvIII-mediated transactivation of receptor tyrosine kinases in glioma: mechanism and therapeutic implications. Oncogene (2015) 0.92
Analysis of receptor tyrosine kinase internalization using flow cytometry. Methods Mol Biol (2008) 0.90
An E3 ubiquitin ligase: c-Cbl: a new therapeutic target of lung cancer. Cancer (2011) 0.89
Molecular mechanisms of SH2- and PTB-domain-containing proteins in receptor tyrosine kinase signaling. Cold Spring Harb Perspect Biol (2013) 0.89
Functional cooperation between c-Cbl and Src-like adaptor protein 2 in the negative regulation of T-cell receptor signaling. Mol Cell Biol (2002) 0.88
Targeting HGF/c-MET induces cell cycle arrest, DNA damage, and apoptosis for primary effusion lymphoma. Blood (2015) 0.86
The LRIG family: enigmatic regulators of growth factor receptor signaling. Endocr Relat Cancer (2014) 0.86
Targeting MET in Lung Cancer: Will Expectations Finally Be MET? J Thorac Oncol (2016) 0.85
Met kinase-dependent loss of the E3 ligase Cbl in gastric cancer. J Biol Chem (2012) 0.83
Alterations of host cell ubiquitination machinery by pathogenic bacteria. Front Cell Infect Microbiol (2015) 0.83
Ezrin ubiquitylation by the E3 ubiquitin ligase, WWP1, and consequent regulation of hepatocyte growth factor receptor activity. PLoS One (2012) 0.83
Regulation of MET receptor tyrosine kinase signaling by suppressor of cytokine signaling 1 in hepatocellular carcinoma. Oncogene (2015) 0.83
Identification of a novel MET mutation in high-grade glioma resulting in an auto-active intracellular protein. Acta Neuropathol (2015) 0.82
The tyrosine kinase c-Met contributes to the pro-tumorigenic function of the p38 kinase in human bile duct cholangiocarcinoma cells. J Biol Chem (2012) 0.82
Tensin-4-dependent MET stabilization is essential for survival and proliferation in carcinoma cells. Dev Cell (2014) 0.82
Role of mesenchymal-epithelial transition amplification in resistance to anti-epidermal growth factor receptor agents. Ann Transl Med (2015) 0.81
Redundant roles for Met docking site tyrosines and the Gab1 pleckstrin homology domain in InlB-mediated entry of Listeria monocytogenes. Infect Immun (2005) 0.81
Dysregulation of the Met pathway in non-small cell lung cancer: implications for drug targeting and resistance. Transl Lung Cancer Res (2015) 0.80
Met receptor tyrosine kinase degradation is altered in response to the leucine-rich repeat of the Listeria invasion protein internalin B. J Biol Chem (2008) 0.80
HGF-MET in cancer progression and biomarker discovery. Cancer Sci (2017) 0.80
Cbl-family ubiquitin ligases and their recruitment of CIN85 are largely dispensable for epidermal growth factor receptor endocytosis. Int J Biochem Cell Biol (2014) 0.79
cMET in NSCLC: Can We Cut off the Head of the Hydra? From the Pathway to the Resistance. Cancers (Basel) (2015) 0.78
MET expression and copy number status in clear-cell renal cell carcinoma: prognostic value and potential predictive marker. Oncotarget (2016) 0.77
Induction of c-Cbl contributes to anti-cancer effects of HDAC inhibitor in lung cancer. Oncotarget (2015) 0.77
MET Exon 14 Alterations in Lung Cancer: Exon Skipping Extends Half-Life. Clin Cancer Res (2016) 0.76
Signal transduction of fertilization in frog eggs and anti-apoptotic mechanism in human cancer cells: common and specific functions of membrane microdomains. Open Biochem J (2008) 0.76
MET: roles in epithelial-mesenchymal transition and cancer stemness. Ann Transl Med (2017) 0.75
Mutations Preventing Regulated Exon Skipping in MET Cause Osteofibrous Dysplasia. Am J Hum Genet (2015) 0.75
Molecular mechanisms of activating c-MET in KSHV+ primary effusion lymphoma. Oncotarget (2017) 0.75
The Role of BCA2 in the Endocytic Trafficking of EGFR and Significance as a Prognostic Biomarker in Cancer. J Cancer (2016) 0.75
MET receptor variant R970C favors calpain-dependent generation of a fragment promoting epithelial cell scattering. Oncotarget (2017) 0.75
MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy. Ann Transl Med (2017) 0.75
Role of met axis in head and neck cancer. Cancers (Basel) (2013) 0.75
Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges. Nat Rev Clin Oncol (2017) 0.75
Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature (1984) 5.85
c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. Genes Dev (1998) 5.31
Mechanism of met oncogene activation. Cell (1986) 4.20
Cbl: many adaptations to regulate protein tyrosine kinases. Nat Rev Mol Cell Biol (2001) 4.11
Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors. Proc Natl Acad Sci U S A (1987) 3.99
The Wnt/Ca2+ pathway: a new vertebrate Wnt signaling pathway takes shape. Trends Genet (2000) 3.91
The E mu-myc transgenic mouse. A model for high-incidence spontaneous lymphoma and leukemia of early B cells. J Exp Med (1988) 3.80
The c-myc oncogene perturbs B lymphocyte development in E-mu-myc transgenic mice. Cell (1986) 3.72
The human met oncogene is related to the tyrosine kinase oncogenes. Nature (1985) 3.46
Evidence for extrathymic changes in the T cell receptor gamma/delta repertoire. J Exp Med (1990) 3.38
InIB-dependent internalization of Listeria is mediated by the Met receptor tyrosine kinase. Cell (2000) 3.31
Protein kinase C is differentially stimulated by Wnt and Frizzled homologs in a G-protein-dependent manner. Curr Biol (1999) 3.25
Direct presentation of nonpeptide prenyl pyrophosphate antigens to human gamma delta T cells. Immunity (1995) 3.12
Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. Oncogene (2009) 2.86
Preliminary epidemiological assessment of MERS-CoV outbreak in South Korea, May to June 2015. Euro Surveill (2015) 2.77
Lack of correlation between exercise capacity and indexes of resting left ventricular performance in heart failure. Am J Cardiol (1981) 2.74
Tissue hyperplasia and enhanced T-cell signalling via ZAP-70 in c-Cbl-deficient mice. Mol Cell Biol (1998) 2.69
Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor. Mol Cell Biol (1992) 2.53
Thematic analysis of the experience of making a decision to place a family member with Alzheimer's disease in a special care unit. Res Nurs Health (2001) 2.49
Novel vertebrate nucleoporins Nup133 and Nup160 play a role in mRNA export. J Cell Biol (2001) 2.35
Tau interacts with src-family non-receptor tyrosine kinases. J Cell Sci (1998) 2.11
The tyrosine phosphatase SHP-2 is required for sustained activation of extracellular signal-regulated kinase and epithelial morphogenesis downstream from the met receptor tyrosine kinase. Mol Cell Biol (2000) 2.07
Activation of cdc42, rac, PAK, and rho-kinase in response to hepatocyte growth factor differentially regulates epithelial cell colony spreading and dissociation. Mol Biol Cell (2000) 2.00
The sequences of the human and mouse c-cbl proto-oncogenes show v-cbl was generated by a large truncation encompassing a proline-rich domain and a leucine zipper-like motif. Oncogene (1991) 1.98
Reprogramming of the tumour microenvironment by stromal PTEN-regulated miR-320. Nat Cell Biol (2011) 1.98
Biology of the human gamma delta T-cell receptor. Immunol Rev (1991) 1.97
Tumour induction by activated abl involves tyrosine phosphorylation of the product of the cbl oncogene. EMBO J (1994) 1.94
Molecular mechanism for the Shp-2 tyrosine phosphatase function in promoting growth factor stimulation of Erk activity. Mol Cell Biol (2000) 1.94
RING finger mutations that abolish c-Cbl-directed polyubiquitination and downregulation of the EGF receptor are insufficient for cell transformation. Mol Cell (2001) 1.91
Alternative splicing generates isoforms of the met receptor tyrosine kinase which undergo differential processing. Mol Cell Biol (1991) 1.90
The tyrosine kinase regulator Cbl enhances the ubiquitination and degradation of the platelet-derived growth factor receptor alpha. Proc Natl Acad Sci U S A (1998) 1.89
The Cbl phosphotyrosine-binding domain selects a D(N/D)XpY motif and binds to the Tyr292 negative regulatory phosphorylation site of ZAP-70. J Biol Chem (1997) 1.87
Hepatocyte growth factor-induced scatter of Madin-Darby canine kidney cells requires phosphatidylinositol 3-kinase. J Biol Chem (1995) 1.82
A C. elegans E/Daughterless bHLH protein marks neuronal but not striated muscle development. Development (1997) 1.81
Gamma delta T lymphocytes in human tuberculosis. J Infect Dis (1992) 1.78
Identification of an atypical Grb2 carboxyl-terminal SH3 domain binding site in Gab docking proteins reveals Grb2-dependent and -independent recruitment of Gab1 to receptor tyrosine kinases. J Biol Chem (2000) 1.76
V gamma 2V delta 2 TCR-dependent recognition of non-peptide antigens and Daudi cells analyzed by TCR gene transfer. J Immunol (1995) 1.73
The protein product of the c-cbl protooncogene is the 120-kDa tyrosine-phosphorylated protein in Jurkat cells activated via the T cell antigen receptor. J Biol Chem (1994) 1.72
Complementation of the ionizing radiation sensitivity, DNA end binding, and V(D)J recombination defects of double-strand break repair mutants by the p86 Ku autoantigen. Proc Natl Acad Sci U S A (1995) 1.72
A longitudinal study of risk factors for the occurrence, duration and severity of menstrual cramps in a cohort of college women. Br J Obstet Gynaecol (1996) 1.71
From Tpr-Met to Met, tumorigenesis and tubes. Oncogene (2007) 1.69
c-Cbl is transiently tyrosine-phosphorylated, ubiquitinated, and membrane-targeted following CSF-1 stimulation of macrophages. J Biol Chem (1996) 1.69
New genes for male accessory gland proteins in Drosophila melanogaster. Insect Biochem Mol Biol (1997) 1.68
The Gab1 PH domain is required for localization of Gab1 at sites of cell-cell contact and epithelial morphogenesis downstream from the met receptor tyrosine kinase. Mol Cell Biol (1999) 1.67
Tyrosine phosphorylation of the c-cbl proto-oncogene protein product and association with epidermal growth factor (EGF) receptor upon EGF stimulation. J Biol Chem (1995) 1.65
Characterization of the TPR-MET oncogene p65 and the MET protooncogene p140 protein-tyrosine kinases. Proc Natl Acad Sci U S A (1988) 1.64
Dimerization mediated through a leucine zipper activates the oncogenic potential of the met receptor tyrosine kinase. Mol Cell Biol (1993) 1.64
Three additional DNA polymorphisms in the met gene and D7S8 locus: use in prenatal diagnosis of cystic fibrosis. J Pediatr (1987) 1.63
Structure, tissue-specific expression, and transforming activity of the mouse met protooncogene. Cell Growth Differ (1990) 1.62
The evolutionarily conserved N-terminal region of Cbl is sufficient to enhance down-regulation of the epidermal growth factor receptor. J Biol Chem (2000) 1.60
Analysis of neoplasms induced by Cas-Br-M MuLV tumor extracts. J Immunol (1986) 1.58
Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma. Am J Pathol (1996) 1.58
Overexpression of c-met proto-oncogene but not epidermal growth factor receptor or c-erbB-2 in primary human colorectal carcinomas. Oncogene (1992) 1.57
Cbl-mediated negative regulation of the Syk tyrosine kinase. A critical role for Cbl phosphotyrosine-binding domain binding to Syk phosphotyrosine 323. J Biol Chem (1998) 1.57
Study of the mass and spin-parity of the Higgs boson candidate via its decays to Z boson pairs. Phys Rev Lett (2013) 1.56
Acute anterior radiculitis associated with West Nile virus infection. J Neurol Neurosurg Psychiatry (2003) 1.55
Activation of the JNK pathway is essential for transformation by the Met oncogene. EMBO J (1997) 1.55
Clinical and neurocognitive effects of clozapine and risperidone in treatment-refractory schizophrenic patients: a prospective study. J Clin Psychiatry (1998) 1.53
A predominance of the T cell receptor V gamma 2/V delta 2 subset in human mycobacteria-responsive T cells suggests germline gene encoded recognition. J Immunol (1991) 1.52
A novel phosphotyrosine-binding domain in the N-terminal transforming region of Cbl interacts directly and selectively with ZAP-70 in T cells. J Biol Chem (1996) 1.50
Expression of scatter factor and c-met receptor in benign and malignant breast tissue. Cancer (1997) 1.50
Refined linkage map of chromosome 7 in the region of the cystic fibrosis gene. Am J Hum Genet (1988) 1.48
Association of the multisubstrate docking protein Gab1 with the hepatocyte growth factor receptor requires a functional Grb2 binding site involving tyrosine 1356. J Biol Chem (1997) 1.48
Involvement of hepatocyte growth factor in kidney development. Dev Biol (1994) 1.47
Extensive junctional diversity of rearranged human T cell receptor delta genes. Science (1988) 1.47
Cbl-mediated negative regulation of platelet-derived growth factor receptor-dependent cell proliferation. A critical role for Cbl tyrosine kinase-binding domain. J Biol Chem (1999) 1.46
Highly sensitive multiplex assay for detection of human immunodeficiency virus type 1 and hepatitis C virus RNA. J Clin Microbiol (2002) 1.46
The non-receptor tyrosine kinase Syk is a target of Cbl-mediated ubiquitylation upon B-cell receptor stimulation. EMBO J (2001) 1.43
Crucial role of TCR gamma chain junctional region in prenyl pyrophosphate antigen recognition by gamma delta T cells. J Immunol (1998) 1.42
Cardiac allograft valvulopathy: a case of donor-anorexigen-induced valvular disease. Ann Thorac Surg (1999) 1.40
Association of a chromosome deletion syndrome with a fragile site within the proto-oncogene CBL2. Nature (1995) 1.38
Characterization of a third form of the human T cell receptor gamma/delta. J Exp Med (1988) 1.38
Evidence for clonal selection of gamma/delta T cells in response to a human pathogen. J Exp Med (1991) 1.38
Case management model for a community-based multiple sclerosis clinic. Clin Nurse Spec (2000) 1.38
Hepatocyte growth factor/scatter factor is an autocrine factor for human normal bronchial epithelial and lung carcinoma cells. Cell Growth Differ (1993) 1.36
The Cbl proto-oncogene product negatively regulates the Src-family tyrosine kinase Fyn by enhancing its degradation. Mol Cell Biol (2000) 1.34
Increased frequency of T cell receptor V alpha 12.1 expression on CD8+ T cells: evidence that V alpha participates in shaping the peripheral T cell repertoire. J Exp Med (1991) 1.33
Phosphotyrosine binding domain-dependent upregulation of the platelet-derived growth factor receptor alpha signaling cascade by transforming mutants of Cbl: implications for Cbl's function and oncogenicity. Mol Cell Biol (1997) 1.33
Differential expression of Met/hepatocyte growth factor receptor in subtypes of non-small cell lung cancers. Lung Cancer (1998) 1.32
Ethnic differences in birthweight: the role of lifestyle and other factors. Am J Public Health (1997) 1.32
The linker phosphorylation site Tyr292 mediates the negative regulatory effect of Cbl on ZAP-70 in T cells. J Immunol (2000) 1.31
Efficient cellular transformation by the Met oncoprotein requires a functional Grb2 binding site and correlates with phosphorylation of the Grb2-associated proteins, Cbl and Gab1. J Biol Chem (1997) 1.30
Tyrosine phosphorylation of Cbl upon epidermal growth factor (EGF) stimulation and its association with EGF receptor and downstream signaling proteins. J Biol Chem (1996) 1.29
The SH3 domain-binding T cell tyrosyl phosphoprotein p120. Demonstration of its identity with the c-cbl protooncogene product and in vivo complexes with Fyn, Grb2, and phosphatidylinositol 3-kinase. J Biol Chem (1995) 1.28
Fyn, Yes, and Syk phosphorylation sites in c-Cbl map to the same tyrosine residues that become phosphorylated in activated T cells. J Biol Chem (1998) 1.28
Histologic and cell surface antigen studies of hematopoietic tumors induced by Cas-Br-M murine leukemia virus. J Natl Cancer Inst (1984) 1.27
Pathways downstream of Shc and Grb2 are required for cell transformation by the tpr-Met oncoprotein. J Biol Chem (1996) 1.26
Simple elective cholecystectomy: to drain or not. Am J Surg (1990) 1.25